Articles from Ensoma

Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced the presentation of initial clinical data from the first participant dosed in its Phase 1/2 trial of EN-374 for the treatment of X-linked chronic granulomatous disease (X-CGD) at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15 in Boston. The data represent the first reported clinical experience with in vivo hematopoietic stem cell (HSC)-directed therapy, from which the patient has the potential to create a continuous source of therapeutic immune and blood cells to treat disease.

Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) clearance of the clinical trial authorization (CTA) application for its lead program EN-374, an in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for the treatment of X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder. The company announced last week that the first U.S. patient in the multinational Phase 1/2 trial was successfully dosed with EN-374.

Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial of EN-374. EN-374 is an in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for the treatment of X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder.

Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced new preclinical data demonstrating proof-of-concept for its in vivo, HSC-derived CAR-M, NK, and T cell platform, including its potential to durably generate lineage-restricted CAR cells in solid tumors. The data will be presented in two poster sessions this week at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in National Harbor, Md.

Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced it will present new data from the company’s in vivo HSC engineering platform in two poster sessions at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, hosted November 5-9 in National Harbor, Md.

Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors. The financing will support Ensoma’s recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD) and support key clinical readouts, while continuing to expand and refine the potential global impact of the company’s in vivo engineered cell therapy platform in immuno-oncology and sickle cell disease.

Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for its lead program EN-374 in X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder.

Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies designed to precisely and durably engineer the hematopoietic system to treat chronic diseases, today announced it will present preclinical data and manufacturing advancements at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, hosted May 13-17 in New Orleans.

Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system, today announced the U.S. Food and Drug Administration (FDA) has granted both rare pediatric disease and orphan drug designations to the company’s lead program, EN-374, for the treatment of X-linked chronic granulomatous disease (X-CGD). Ensoma anticipates it will submit an investigational new drug application (IND) for EN-374 in the first half of 2025.

Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system, today unveiled its three lead programs targeting genetic, immune and oncological diseases. These innovative programs leverage Ensoma’s in vivo hematopoietic stem cell (HSC) engineering platform and aim to address critical unmet needs in chronic granulomatous disease (CGD), sickle cell disease (SCD) and solid tumors. Ensoma’s in vivo HSC engineering approach has the potential to offer greatly improved patient access to therapy and a vastly reduced treatment burden.

Ensoma, a genomic medicines company advancing the future of medicine through precision one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the appointment of Jon Garen as chief corporate development and business officer.

Ensoma, a genomic medicines company advancing the future of medicine through precision one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the appointment of Jim Burns, Ph.D., as chief executive officer and a member of the company’s board of directors.

Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million. The $50 million was contributed by new investors Kite, a Gilead Company (Nasdaq: GILD), Bioluminescence Ventures and Delos Capital and by existing investor SymBiosis. These investors joined a syndicate of leading healthcare funds to advance the development of Ensoma’s Engenious™ in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology, genetic disease and other therapeutic applications.

Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within, today announced the closing of its previously announced acquisition of Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. The closing follows recent clearance by the Danish Business Authority pursuant to Danish foreign direct investment laws.

Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the completion of an $85 million financing. Proceeds will enable Ensoma to advance the development of its Engenious™ in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications. The company also announced it has entered into a definitive agreement to acquire Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology.

Ensoma, a gene therapy company advancing the future of medicine through precision in vivo engineering of blood and immune cells, today announced additions to the Company’s scientific advisory board (SAB) – Crystal Mackall, M.D., of the Stanford University School of Medicine, and Harry Malech, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). They join existing SAB members, Co-founder and Chairman Hans-Peter Kiem, M.D., Ph.D., of Fred Hutchinson Cancer Research Center (Fred Hutch); Anja Ehrhardt, Ph.D., of Universität Witten/Herdecke; Vijay Sankaran, M.D., Ph.D., of Boston Children’s Hospital; and Mark Walters, M.D., of University of California, San Francisco (UCSF).

Ensoma, a gene therapy company advancing the future of medicine through precision in vivo engineering of blood and immune cells, today announced the appointment of Emile Nuwaysir, Ph.D., as president, chief executive officer and member of the company’s board of directors. In conjunction with the CEO appointment, Paula Soteropoulos, executive chairman of Ensoma, will transition to the role of chairman of the board, and Kush M. Parmar, M.D., Ph.D., managing partner of 5AM ventures, will continue to serve as a member of the board.